WILMINGTON, Mass. / May 31, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice (CGMP) biologics manufacturing facility in Oklahoma City, OK. Deployed on-site at a client’s facility, RightSource is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable quality control (QC) more accessible to a broader reach of companies.
Through this model, Charles River, in close collaboration with Wheeler, will set up a CGMP testing lab, on-site at Wheeler’s facility. This platform-based satellite lab will be operated by Charles River employees who will utilize Charles River’s quality management systems, test methods, and standard operating procedures (SOPs) to support all QC testing needs for Wheeler and its third-party clients.
Outsourced Biologics Testing, Offered On-Site
The RightSource platform is a novel insourcing solution serving biotech and biopharmaceutical companies with the panel of assays they deem necessary for their biologics manufacturing program to have on site. Unlike standard staffing solutions, RightSource offers clients the expertise to bring Charles River’s proprietary assays in-house, with the same quality and scientific platforms used at Charles River’s outsourcing facilities. Having a RightSource program in-house enables clients to leverage Charles River’s wider network of regulatory, scientific consultation and biologics testing support, and will deliver rapid turnaround times and expedited batch release on behalf of Wheeler’s clients.
As Charles River continues investing in digitalization, all RightSource clients will automatically receive enhanced products and services, increasing the value of the partnership as time goes on. The RightSource/Wheeler lab will be operational in the third quarter of 2023 and is anticipated to start in-process and release testing by the end of the year.
Approved Quotes
About Wheeler Bio
Wheeler Bio is a biomanufacturing pioneer, founded by a team of industry experts and strategic investors who believe a different CDMO model is needed to help innovators reach their clinical milestones faster. Wheeler’s novel hub-and-spoke operational model, centered in the biomanufacturing metro of Oklahoma City, and integrated with biotechs and discovery CROs, will revolutionize the speed of drug development. Wheeler Bio’s technology platform, Portable CMC™, simplifies the path between drug discovery and clinical manufacturing by providing a new bridge for translating discoveries to IND filing. Innovators benefit from increased momentum during technology transfer, shorter timelines, reduced risk, and lower costs. Additional information can be obtained by visiting www.wheelerbio.com, or by following Wheeler Bio on LinkedIn.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Last Trade: | US$185.77 |
Daily Change: | 3.62 1.99 |
Daily Volume: | 909,288 |
Market Cap: | US$9.500B |
December 05, 2024 November 11, 2024 November 06, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB